Kindred

EyeCare Partners Announces Joel Day as New Chief Financial Officer

Retrieved on: 
금요일, 5월 3, 2024
Finance, Accounting, Health, Professional Services, Optical, Sale, CFO, Kindred Healthcare, Kindred, Forecasting, Life, Controller, RCM, Patient, Multimedia, Growth, Strategic planning, Management

EyeCare Partners, the nation’s leading provider of clinically integrated eye care, announced that Joel Day has been named Executive Vice President – Finance and will take the Chief Financial Officer role, effective June 1.

Key Points: 
  • EyeCare Partners, the nation’s leading provider of clinically integrated eye care, announced that Joel Day has been named Executive Vice President – Finance and will take the Chief Financial Officer role, effective June 1.
  • View the full release here: https://www.businesswire.com/news/home/20240503167955/en/
    He will lead and have responsibility for the strategic planning, implementation and management of all EyeCare Partners Finance activities, including accounting, business planning, budgeting, forecasting, revenue cycle management (RCM) and procurement.
  • Day will succeed Bob Gold, who has shared his intent to depart the organization, effective May 31.
  • “Joel brings to EyeCare Partners three decades of deep, meaningful experience in health care across all finance functions at companies both in public and private settings,” said Chris Throckmorton, Chief Executive Officer.

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers

Retrieved on: 
목요일, 5월 2, 2024
Neoplasm, Medication, Cancer, Laboratory, Bias, Innovation, Big Pharma, University of Oxford, Octopus Group, Health care, Recurrence, Kindred, Vaccine, CRUK, Cancer Research Institute, Patient, LC-MS/MS, MHRA, Immune system, Associate, Precision, Growth

OXFORD, England, May 2, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8m seed funding round led by Octopus Ventures.  The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors. The total funds raised combine new equity investment and a prestigious non-dilutive award from Innovate UK's Future Economy Investor Partnership scheme.

Key Points: 
  • Since incorporation in 2021, Infinitopes has moved swiftly to cement its leadership position in cancer vaccines by overcoming three key challenges in the field.
  • Firstly, using its Precision ImmunomicsTM antigen discovery technologies, the Company can identify and rank tumour signatures, without prior bias, enabling the accurate selection of novel, synergistic tumour targets.
  • Secondly, Infinitopes continues to develop safe and effective, proprietary vector delivery systems, capable of stimulating durable T-cell responses necessary to prevent the recurrence of life-threatening cancer metastases.
  • Infinitopes' lead asset, a novel cancer vaccine called ITOP1, is scheduled to commence a phase I/IIa study in first line cancer patients in the third quarter of 2024.

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers

Retrieved on: 
화요일, 4월 30, 2024
Neoplasm, Medication, Cancer, Laboratory, Bias, Innovation, Big Pharma, University of Oxford, Octopus Group, Health care, Recurrence, Kindred, Vaccine, CRUK, Cancer Research Institute, Patient, LC-MS/MS, MHRA, Immune system, Associate, Precision, Growth

OXFORD, England, April 30, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8m seed funding round led by Octopus Ventures.  The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors. The total funds raised combine new equity investment and a prestigious non-dilutive award from Innovate UK's Future Economy Investor Partnership scheme.

Key Points: 
  • Since incorporation in 2021, Infinitopes has moved swiftly to cement its leadership position in cancer vaccines by overcoming three key challenges in the field.
  • Firstly, using its Precision ImmunomicsTM antigen discovery technologies, the Company can identify and rank tumour signatures, without prior bias, enabling the accurate selection of novel, synergistic tumour targets.
  • Secondly, Infinitopes continues to develop safe and effective, proprietary vector delivery systems, capable of stimulating durable T-cell responses necessary to prevent the recurrence of life-threatening cancer metastases.
  • Infinitopes' lead asset, a novel cancer vaccine called ITOP1, is scheduled to commence a phase I/IIa study in first line cancer patients in the third quarter of 2024.

Envision Healthcare Appoints Jason Owen President and CEO

Retrieved on: 
월요일, 4월 15, 2024
General Health, Other Health, Health, Practice Management, Managed Care, CFO, ABA, Master of Business Administration, Safety, Envision, Health care, Small Smiles Dental Centers, Business administration, Kindred, Business, Applied behavior analysis, Bachelor of Business Administration, Senior, Patient, Acquisition, Medicine, Multimedia, Hanger, Inc., Envision Healthcare, Home, Georgia State University, Georgia Southern University, Operation, Management

Envision Healthcare, a leading national medical group, today announced the appointment of Jason Owen as President and Chief Executive Officer (CEO), effective April 15, 2024.

Key Points: 
  • Envision Healthcare, a leading national medical group, today announced the appointment of Jason Owen as President and Chief Executive Officer (CEO), effective April 15, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240415923764/en/
    Envision Healthcare, a leading national medical group, today announced the appointment of Jason Owen as President and Chief Executive Officer (CEO).
  • (Photo: Business Wire)
    Owen joins Envision from BlueSprig, one of the nation’s leading providers of Applied Behavior Analysis (ABA) therapy for children, where he served as President and CEO.
  • “He is a tenured healthcare leader who is passionate about improving healthcare access and quality, especially for fragile patient populations.

Bulletin from Kindred Group plc's Annual General Meeting

Retrieved on: 
금요일, 4월 26, 2024
Kindred Group, GBP, Kindred, Committee, AGM, Management

SLIEMA, Malta, April 26, 2024 /PRNewswire/ -- At Kindred Group plc's ("Kindred") annual general meeting held on 26 April 2024 (the "AGM") 35.01 per cent in nominal value of the total shares/Swedish depository receipts ("SDRs") in issue were represented.

Key Points: 
  • SLIEMA, Malta, April 26, 2024 /PRNewswire/ -- At Kindred Group plc's ("Kindred") annual general meeting held on 26 April 2024 (the "AGM") 35.01 per cent in nominal value of the total shares/Swedish depository receipts ("SDRs") in issue were represented.
  • At the AGM, Evert Carlsson, James H. Gemmel, Heidi Skogster, Cédric Boireau, Jonas Jansson, Andy McCue, Martin Randel and Kenneth Shea were re-elected as Directors of the Company.
  • In addition, Evert Carlsson was re-appointed as the Chairman of the Board.
  • The AGM also resolved that, until the general meeting of the shareholders decides otherwise, the Nomination Committee shall consist of not less than four and not more than five members.

Bulletin from Kindred Group plc's Annual General Meeting

Retrieved on: 
금요일, 4월 26, 2024
Kindred Group, GBP, Kindred, Committee, AGM, Management

SLIEMA, Malta, April 26, 2024 /PRNewswire/ -- At Kindred Group plc's ("Kindred") annual general meeting held on 26 April 2024 (the "AGM") 35.01 per cent in nominal value of the total shares/Swedish depository receipts ("SDRs") in issue were represented.

Key Points: 
  • SLIEMA, Malta, April 26, 2024 /PRNewswire/ -- At Kindred Group plc's ("Kindred") annual general meeting held on 26 April 2024 (the "AGM") 35.01 per cent in nominal value of the total shares/Swedish depository receipts ("SDRs") in issue were represented.
  • At the AGM, Evert Carlsson, James H. Gemmel, Heidi Skogster, Cédric Boireau, Jonas Jansson, Andy McCue, Martin Randel and Kenneth Shea were re-elected as Directors of the Company.
  • In addition, Evert Carlsson was re-appointed as the Chairman of the Board.
  • The AGM also resolved that, until the general meeting of the shareholders decides otherwise, the Nomination Committee shall consist of not less than four and not more than five members.

Notice to Kindred Group plc AGM

Retrieved on: 
금요일, 3월 22, 2024
Remuneration, Financial statement, KPMG, Chair, Documentation, PwC, FDJ, Exercise, Committee, Date, European Parliament, White, Proxy, Telephone, Euroclear, Knowledge, AGM, Kindred, Kindred Group, Audit committee, White & Case, GBP, Bank statement, Commission, SDR, Council, Annual report, European, BankID, CVS, Nasdaq Stockholm, Companies Act, Report, Audit

SLIEMA, Malta, March 22, 2024 /PRNewswire/ -- NOTICE IS HEREBY GIVEN that THE ANNUAL GENERAL MEETING ("AGM") of Kindred Group plc (C 39017) (the "Company") will be held on Friday 26 April 2024 at 10:00 CEST at Kindred's office, Regeringsgatan 25, Stockholm, Sweden.

Key Points: 
  • SLIEMA, Malta, March 22, 2024 /PRNewswire/ -- NOTICE IS HEREBY GIVEN that THE ANNUAL GENERAL MEETING ("AGM") of Kindred Group plc (C 39017) (the "Company") will be held on Friday 26 April 2024 at 10:00 CEST at Kindred's office, Regeringsgatan 25, Stockholm, Sweden.
  • Holders of SDRs who wish to exercise their voting right at the AGM must:
    (ii) no later than Friday 19 April 2024 23:59 CET either register their intention to attend the AGM, or exercise their voting rights, by following the link https://anmalan.vpc.se/euroclearproxy , and clicking through to Kindred Group, and logging in with BankID.
  • It is proposed that the AGM conducts the following business:
    Standards for the year ended 31 December 2023, together with
    the Report of the Auditors.
  • CVs for the current Directors are to be found on pages 60-62 in the Kindred Group plc Annual Report for 2023 and on the Company's website.

Notice to Kindred Group plc AGM

Retrieved on: 
금요일, 3월 22, 2024
Remuneration, Financial statement, KPMG, Chair, Documentation, PwC, FDJ, Exercise, Committee, Date, European Parliament, White, Proxy, Telephone, Euroclear, Knowledge, AGM, Kindred, Kindred Group, Audit committee, White & Case, GBP, Bank statement, Commission, SDR, Council, Annual report, European, BankID, CVS, Nasdaq Stockholm, Companies Act, Report, Audit

SLIEMA, Malta , March 20, 2024 /PRNewswire/ -- NOTICE IS HEREBY GIVEN that THE ANNUAL GENERAL MEETING ("AGM") of Kindred Group plc (C 39017) (the "Company") will be held on Friday 26 April 2024 at 10:00 CEST at Kindred's office, Regeringsgatan 25, Stockholm, Sweden.

Key Points: 
  • SLIEMA, Malta , March 20, 2024 /PRNewswire/ -- NOTICE IS HEREBY GIVEN that THE ANNUAL GENERAL MEETING ("AGM") of Kindred Group plc (C 39017) (the "Company") will be held on Friday 26 April 2024 at 10:00 CEST at Kindred's office, Regeringsgatan 25, Stockholm, Sweden.
  • Holders of SDRs who wish to exercise their voting right at the AGM must:
    (ii) no later than Friday 19 April 2024 23:59 CET either register their intention to attend the AGM, or exercise their voting rights, by following the link https://anmalan.vpc.se/euroclearproxy , and clicking through to Kindred Group, and logging in with BankID.
  • It is proposed that the AGM conducts the following business:
    Standards for the year ended 31 December 2023, together with
    the Report of the Auditors.
  • CVs for the current Directors are to be found on pages 60-62 in the Kindred Group plc Annual Report for 2023 and on the Company's website.

Bulletin from Kindred Group plc's Extraordinary General Meeting

Retrieved on: 
금요일, 3월 15, 2024
EGM, Kindred, Law, Kindred Group, Memorandum, Companies Act, Malta Business Registry

SLIEMA, Malta, March 15, 2024 /PRNewswire/ -- Today at the extraordinary general meeting of Kindred Group plc ('Kindred' or the 'Company') the meeting resolved to approve the Board of Directors' proposal to amend the Company's current Memorandum and Articles of Association to, inter alia, include squeeze-out rights for an offeror.

Key Points: 
  • SLIEMA, Malta, March 15, 2024 /PRNewswire/ -- Today at the extraordinary general meeting of Kindred Group plc ('Kindred' or the 'Company') the meeting resolved to approve the Board of Directors' proposal to amend the Company's current Memorandum and Articles of Association to, inter alia, include squeeze-out rights for an offeror.
  • In accordance with Article 135 of the Companies Act (Cap.
  • 386 of the Laws of Malta) the adoption of the resolution required approval by not less than 75 percent of the nominal value of the shares/SDRs represented and entitled to vote at the EGM.
  • As this requirement was fulfilled, the resolution was passed and the new Memorandum and Articles of Association will be submitted to the Malta Business Registry for registration shortly.

Bulletin from Kindred Group plc's Extraordinary General Meeting

Retrieved on: 
금요일, 3월 15, 2024
EGM, Kindred, Law, Kindred Group, Memorandum, Companies Act, Malta Business Registry

SLIEMA, Malta, March 15, 2024 /PRNewswire/ -- Today at the extraordinary general meeting of Kindred Group plc ('Kindred' or the 'Company') the meeting resolved to approve the Board of Directors' proposal to amend the Company's current Memorandum and Articles of Association to, inter alia, include squeeze-out rights for an offeror.

Key Points: 
  • SLIEMA, Malta, March 15, 2024 /PRNewswire/ -- Today at the extraordinary general meeting of Kindred Group plc ('Kindred' or the 'Company') the meeting resolved to approve the Board of Directors' proposal to amend the Company's current Memorandum and Articles of Association to, inter alia, include squeeze-out rights for an offeror.
  • In accordance with Article 135 of the Companies Act (Cap.
  • 386 of the Laws of Malta) the adoption of the resolution required approval by not less than 75 percent of the nominal value of the shares/SDRs represented and entitled to vote at the EGM.
  • As this requirement was fulfilled, the resolution was passed and the new Memorandum and Articles of Association will be submitted to the Malta Business Registry for registration shortly.